

# NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

## GUIDANCE EXECUTIVE (GE)

### Consideration of consultation responses on review proposal

#### Review of Review of TA101 Docetaxel for the treatment of hormone refractory prostate cancer

This guidance was issued in June 2006, with a review date of June 2009.

#### Background

At the GE meeting on 9 June 2009 it was agreed we would consult on the review plans for this guidance. A four-week consultation has been conducted with consultees and commentators and the responses are presented below.

<b>Proposal put to consultees:</b>	A review of the guidance should be deferred to June 2013. That we consult on the proposal.
------------------------------------	--

GE is asked to consider the original proposal in the light of the comments received from consultees and commentators, together with any responses from the appraisal team. It is asked to agree on the final course of action for the review.

<b>Recommendation post consultation:</b>	A review of the guidance should be deferred to June 2013. That we consult on the proposal.
--	--

<b>Respondent</b>	<b>Response to proposal</b>	<b>Details</b>	<b>Comment from Technology Appraisal</b>
Sanofi-aventis (taxotere)	No objection		Noted
Royal College of Pathologists	Disagree	The college does not know of any new evidence to suggest an immediate review is necessary but suggests that 2011 would be a more appropriate review date	Clarification on date sought from Royal College of Pathologists but no response received.
Institute of Cancer Research	Agree		Noted
Royal College of Nursing	No objection		Noted

British Uro-oncology Group	No comment		Noted
----------------------------	------------	--	-------

**No response received from:**

<b>Consultees</b>	<b>Consultees</b>	<b>Commentators (no right to submit or appeal)</b>
<u>Patient/carer groups</u> <ul style="list-style-type: none"> <li>• Afiya Trust</li> <li>• Age Concern England</li> <li>• Black Health Agency</li> <li>• Bob Champion Cancer Trust</li> <li>• CANCERactive</li> <li>• Cancerbackup</li> <li>• Cancer Black Care</li> <li>• Cancer Equality</li> <li>• Cancer Voices</li> <li>• Chinese National Healthy Living Centre</li> <li>• Confederation of Indian Organisations</li> <li>• Counsel and Care</li> <li>• Equalities National Council</li> <li>• Everyman</li> <li>• Helen Rollason Heal Cancer Charity</li> <li>• Help the Aged</li> <li>• Macmillan Cancer Support</li> <li>• Maggie's Centres</li> <li>• Marie Curie Cancer Care</li> <li>• Muslim Council of Great Britain</li> <li>• Muslim Health Network</li> <li>• National Cancer Alliance</li> <li>• Orchid</li> <li>• PCaSO – Prostate Cancer Network</li> <li>• Prostate Cancer Charity</li> </ul>	<u>Professional groups</u> <ul style="list-style-type: none"> <li>• Association of Cancer Physicians</li> <li>• British Association for Services to the Elderly</li> <li>• British Association of Urological Nurses</li> <li>• British Association of Urological Surgeons</li> <li>• British Geriatrics Society</li> <li>• British Oncological Association</li> <li>• British Prostate Group</li> <li>• British Psychosocial Oncology Society</li> <li>• Cancer Networks Pharmacists Forum</li> <li>• Cancer Research UK</li> <li>• Prostate Brachytherapy Advisory Group</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Physicians, Medical Oncology Joint Special Committee</li> <li>• Royal College of Radiologists</li> <li>• Royal Society of Medicine – Intellectual Disabilities Forum</li> <li>• Society and College of Radiographers</li> <li>• United Kingdom Clinical Pharmacy Association</li> <li>• United Kingdom Oncology Nursing Society</li> </ul>	<u>General</u> <ul style="list-style-type: none"> <li>• Age Concern Cymru</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Cancer Care Cymru</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Medicines and Healthcare Products Regulatory Agency</li> <li>• National Association for Primary Care</li> <li>• National Public Health Service for Wales</li> <li>• NHS Alliance</li> <li>• NHS Confederation</li> <li>• NHS Purchasing and Supply Agency</li> <li>• NHS Quality Improvement Scotland</li> <li>• Scottish Medicines Consortium</li> </ul> <u>Comparator manufacturers</u> <ul style="list-style-type: none"> <li>• Baxter Oncology (mitoxantrone)</li> <li>• Dabur Pharma (mitoxantrone)</li> <li>• Hospira (mitoxantrone)</li> <li>• Pfizer (estramustine)</li> <li>• Teva Pharmaceuticals (mitoxantrone)</li> </ul> <u>Relevant research groups</u> <ul style="list-style-type: none"> <li>• MRC Clinical Trials Unit</li> <li>• National Cancer Research Institute</li> </ul>

Consultees	Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• Prostate Help Association</li> <li>• PSA – Prostate Cancer Support Association</li> <li>• Specialised Healthcare Alliance</li> <li>• South Asian Health Foundation</li> <li>• Sue Ryder Care</li> <li>• Tenovus Cancer Information Centre</li> </ul>	<p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Bath and North East Somerset PCT</li> <li>• Department of Health</li> <li>• Pembrokeshire LHB</li> <li>• Welsh Assembly Government</li> </ul>	<ul style="list-style-type: none"> <li>• National Cancer Research Network</li> <li>• National Institute of Health Research</li> <li>• Ovarian &amp; Prostate Cancer Research Trust</li> <li>• Policy Research Institute on Ageing and Ethnicity</li> <li>• Pro-Cancer Research Foundation</li> <li>• Prostate Cancer Research Foundation</li> <li>• Prostate UK</li> <li>• Radiological Research Trust</li> <li>• Research Institute of the Care of Older People</li> </ul> <p><u>Assessment Group</u></p> <ul style="list-style-type: none"> <li>• National Institute for Health Research Health Technology Assessment Programme</li> </ul> <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> <li>• National Collaborating Centre for Cancer</li> </ul>

**GE paper sign-off:**

Nina Pinwill, Associate Direct, CHTE, NICE  
27 July 2009

**Contributors to this paper:**

Information Specialist: Daniel Tuvey  
Technical Lead: Helen Tucker  
Technical Adviser: Helen Chung  
Project Manager: Natalie Bemrose